A majority of new cases of atherosclerotic cardiovascular disease (CVD) occur in the apparently healthy population. Therefore, primary prevention remains a major public health challenge. Primary prevention of CVD is possible but should be developed in a cost-efficient manner, for example by risk scoring, which involves an estimation of the likelihood of a person developing CVD over a defined period of time. It is an estimate, not a precise calculation, of the absolute risk. It should be emphasized that the CVD risk estimation of a given person, expressed in terms of absolute risk, remains hazardous, very approximate and therefore, at present, elusive. The challenge nowadays is not the need for a more personalized prevention but the failure to act in those who have the potential to benefit.
In the present issue of our Journal, an educational paper is published, developed within the framework of the European Society of Cardiology (ESC) Prevention of CVD Prevention Programme. 1 Here, currently available risk prediction tools are reviewed, and additional support is provided to health professionals on when, with whom and how to use these tools. One should realize that these risk estimation tools should not be used in isolation but as part of a comprehensive strategy to implement guidelines on the primary prevention of CVD.
Competitive athletes

Poor healthy lifestyle implementation
Athletes and people participating in sports or other forms of physical exercise are generally perceived as healthy with a unique lifestyle. However, a small proportion of athletes and sports participants die suddenly from a cardiac condition. 2 The prevention of sudden cardiac arrest or death (SCA or SCD) among athletes and sports participants can be achieved through screening for high-risk cardiovascular conditions (HRCCs), cardiopulmonary resuscitation in unforeseen SCA, the control of major cardiovascular risk factors and abstention from exercise during a viral infection or fever. The control of the major cardiac risk factors (smoking, systemic hypertension, diabetes and dyslipidaemia) in low-risk groups (i.e. young people) achieved through lifestyle change programmes is fundamental rather than the lifelong prescription of preventive drugs. Despite worldwide educational programmes for the prevention of CVD, it seems that these programmes are still to be improved. On the other side, screening athletes for HRCC is advocated by the international cardiac societies and sports governing bodies but associated with important costing. The costs of electrocardiogram-inclusive screening for HRCC, including disease management, ranges between E67 and E90,000 per life-year saved. 3 Presented here are the results of a questionnaire on cardiovascular risk prevention and safety distributed among French amateur rugby players, mostly men (90%) aged <35 years (80%). Most of the 640 participants who completed the questionnaire were unaware of the rule of cardiovascular safety, only 27% attended screening for HRCC (although recommended in France), and showed high use of tobacco, alcohol and highly caffeinated beverages, almost equal to that in the French sedentary population. Thus, as the authors state, a more intensive programme of information and education of all sports participants is needed to improve their knowledge and awareness of good health to prevent cardiac events.
Pre-participation screening in hypertensive athletes
The prevalence of systemic hypertension in the athletic population is not as uncommon as expected (3%), 4 and it represents the most relevant risk factor for CVD also in an apparently healthy population such as athletes. A Task Force from the European Association of Preventive Cardiology, led by Josef Niebauer, present an executive summary of recent presented recommendations for pre-participation screening in competitive sports of athletes with arterial hypertension. Its early recognition is mandatory to avoid fatal major events. The Task Force has further emphasized the importance of the early signs of cardiac target organ damage as well as the blood pressure response to maximal exercise testing. In patients with low or moderate cardiovascular risk, no restriction from competitive sport is required if blood pressure values are normalized. In patients with a high risk or very high risk and adequate control of blood pressure values, participation in all competitive sports is allowed, with the exclusion of power disciplines.
Cardiac rehabilitation in older patients
Although poorly represented in clinical trials, elderly patients have demonstrated benefitting from cardiac rehabilitation, leading to important improvement in functional capacity, coronary risk factors, symptoms, quality of life and psychosocial status. However, many of these improvements fade in the medium to long term if the discharge recommendations, particularly those directed at maintaining physical activity and some form of exercise training, are not followed. 5 In the present issue, Pratesi et al. report a prospective randomized single centre trial focusing on the effect of a longterm follow-up programme after cardiac rehabilitation in an elderly population. At the end of the completion of a four-week outpatient cardiac rehabilitation (post acute coronary syndrome or coronary artery bypass grafting and/or cardiac valve surgery) 160 patients, mean age 80 years, were randomized to a structured home-based exercise programme, closely followed with exercise diary and monthly in-hospital reinforcement, or to a control group who received only a general recommendation to exercise at home. The study results confirmed the feasibility of cardiac rehabilitation programme also in very old individuals and its beneficial effects are maintained over time. However, no differences were observed in functional capacity, quality of life or hospitalization between treatment and control arms. The quite surprising results concerning the neutral effect of more intensive follow-up versus usual care can be explained by the rather selected study population, in good physical condition, with no neuro-psychologic deterioration, and active. Frail, sicker patients, here excluded, have been shown to benefit from a multicomponent intervention based on resistance training, associated with aerobic, balance and flexibility exercises. 6 Resistance exercise training: how much is good?
Endurance training has been the most intensively studied exercise modality in patients with CVD. The implementation of dynamic resistance exercise as an additional exercise mode to aerobic exercises in cardiac rehabilitation regimes is the most recommended approach. 7 However, dynamic strength training protocols are less consensual. The question thus arises as to what dynamic strength training intensity is the best in order to induce the greatest benefits. In this issue, the impact and application of isometric strength training with different intensity are presented and discussed based on a systematic review of the existing literature. The authors confirmed the well-known paradigm that high-intensity strength training (>70% of one-repetition maximum (1-RM); HIST) is more effective to increase muscle strength, with less cardiovascular demand, as opposed to low intensity (at <50% of 1-RM, low number of repetitions; LIST). 8 However, the evidence is still poor, and this review leaves us with more questions than answers. In fact, only 90 individuals were examined in total by crossover design in only six studies, although five out of six studies reported similar findings (no matter whether healthy individuals or CVD patients were examined) and were of good quality. Thus, more studies should be initiated specifically to examine the impact of HIST or LIST bouts in patients with CVD of different types, such as chronic heart failure, peripheral arterial disease and metabolic disease, to mention a few, to validate the current findings from the literature.
Low-density lipoprotein treatment target: the debate continues
Lipid profile management has traditionally played a key role in cardiovascular prevention. In primary prevention, the low-density lipoprotein (LDL) cholesterol threshold is guided by the individual cardiovascular risk profile, whereas in secondary prevention, the current LDL cholesterol goal (i.e. <70 mg/dl) is far from being attained for most patients.
In the current issue, Wang et al. make an appeal for a critical appraisal of clinical practice guidelines when applying the recommendations in populations where interventions have not been properly tested. For instance, in Asian populations high quality evidence is scarce about the significance of a given lipid parameter on overall cardiovascular outcomes as a hard end-point in clinical trials with guaranteed representativeness and adequate sample size. It is concluded on the need to rigorously carry out clinical trials with adequate sample size in different populations, not only to ascertain the efficacy of statin treatment but also to extract information about patient safety. In keeping with this concept, recent studies do not support the current clinical practice guidelines recommending statin treatment without exception in patients older than 75 years. 9 In the population evaluated in this study, statin treatment in patients aged 75 or older without type 2 diabetes was not associated with a reduction in atherosclerotic CVD or in all-cause mortality, even when the incidence of atherosclerotic CVD was significantly higher than the risk thresholds proposed for statin use.
Emotional distress after acute myocardial infarction: an ominous condition, but not easy to correctly identify Depression has been recognized as a risk factor for mortality and medical morbidity in patients with CVD by the American Heart Association and the ESC. One question which has not been clearly answered is whether the longterm risk of mortality is elevated in patients who have symptoms of depression only around the time of an acute myocardial infarction (AMI), or only in those patients who continue to report these symptoms in the long term. Here in a large sample size (57,602 consecutive patients with a first-time AMI), from the national SWEDEHEART register with relatively complete data, the authors found that those who reported emotional distress at two months were more likely to die during the first year after the acute event than were those who reported no distress at that time. Moreover, feeling distressed at two months and at 12 months after acute events was associated with higher CVD and not CVD mortality. Although it provides an incomplete picture, the results of this study and those of previous studies make it clear that single occasion screening for depression may be inadequate to identify high-risk patients or those in need of intervention. The frequency or optimal time to screen cannot be easily inferred from those studies, but a recent meta-analysis of prognostic studies found that the earlier the screening relative to the acute cardiac event, the higher the rate of false positives. Depression identified more than two weeks after the AMI was generally a better predictor of outcomes than depression assessed within the first two weeks. The other problem is the treatment. Although all of the major trials have found that patients whose depression improves have longer event-free survival than those who continue to report significant depression symptoms, 10 only one of the randomized clinical trials in patients with coronary heart disease found that treating depression improved event-free survival. 11 
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